237 related articles for article (PubMed ID: 15287949)
1. Activated protein C levels in Behçet's disease and risk of venous thrombosis.
Navarro S; Ricart JM; Medina P; Vayá A; Villa P; Todolí J; Estellés A; Micó ML; Aznar J; España F
Br J Haematol; 2004 Aug; 126(4):550-6. PubMed ID: 15287949
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cell activation and hypercoagulability in ocular Behçet's disease.
Probst K; Fijnheer R; Rothova A
Am J Ophthalmol; 2004 May; 137(5):850-7. PubMed ID: 15126149
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Strandberg K; Svensson PJ; Ohlin AK
Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
[TBL] [Abstract][Full Text] [Related]
4. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
5. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.
Leiba M; Seligsohn U; Sidi Y; Harats D; Sela BA; Griffin JH; Livneh A; Rosenberg N; Gelernter I; Gur H; Ehrenfeld M
Ann Rheum Dis; 2004 Nov; 63(11):1445-9. PubMed ID: 15479893
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).
Luxembourg B; Schmitt J; Humpich M; Glowatzki M; Dressler D; Seifried E; Lindhoff-Last E
Thromb Haemost; 2009 Oct; 102(4):668-75. PubMed ID: 19806251
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
[TBL] [Abstract][Full Text] [Related]
8. Low plasma activated protein C-protein C inhibitor complex concentration is associated with vascular access failure in hemodialysis patients.
Bakoush O; Ohlin AK; Strandberg K; Kurkus J
Nephron Clin Pract; 2008; 110(3):c151-7. PubMed ID: 18953177
[TBL] [Abstract][Full Text] [Related]
9. Low level of circulating activated protein C is a risk factor for venous thromboembolism.
España F; Vayá A; Mira Y; Medina P; Estellés A; Villa P; Falcó C; Aznar J
Thromb Haemost; 2001 Dec; 86(6):1368-73. PubMed ID: 11776301
[TBL] [Abstract][Full Text] [Related]
10. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.
Espinosa G; Font J; Tàssies D; Vidaller A; Deulofeu R; López-Soto A; Cervera R; Ordinas A; Ingelmo M; Reverter JC
Am J Med; 2002 Jan; 112(1):37-43. PubMed ID: 11812405
[TBL] [Abstract][Full Text] [Related]
11. [Activated protein C resistance in Behçet disease].
Guermazi S; M'Rad S; Lamloum M; Houman MH; Hamza M; Ben Dridi M; Miled M; Dellagi K
Pathol Biol (Paris); 1998 Dec; 46(10):791-5. PubMed ID: 9922996
[TBL] [Abstract][Full Text] [Related]
12. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
[TBL] [Abstract][Full Text] [Related]
13. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
14. Haemostasis in patients with Behçet's disease.
Demirer S; Sengül N; Yerdel MA; Tüzüner A; Ulus AT; Gürler A; Bergqvist D; Siegbahn A; Karacagil S
Eur J Vasc Endovasc Surg; 2000 Jun; 19(6):570-4. PubMed ID: 10873722
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of thrombophilia and venous thromboembolism in total knee arthroplasty.
Chotanaphuti T; Ongnamthip P; Silpipat S; Foojareonyos T; Roschan S; Reumthantong A
J Med Assoc Thai; 2007 Jul; 90(7):1342-7. PubMed ID: 17710975
[TBL] [Abstract][Full Text] [Related]
16. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease.
Mader R; Ziv M; Adawi M; Mader R; Lavi I
J Rheumatol; 1999 Nov; 26(11):2404-8. PubMed ID: 10555901
[TBL] [Abstract][Full Text] [Related]
17. [Is Behçet's disease associated with characteristic abnormalities of coagulation and fibrinolysis? Apropos of 70 case reports].
Conard J; Horellou MH; Wechsler B; Fassin D; Bletry O; Godeau P; Samama M
J Mal Vasc; 1988; 13(3):257-61. PubMed ID: 3171405
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions.
Kamphuisen PW; Eikenboom JC; Vos HL; Pablo R; Sturk A; Bertina RM; Rosendaal FR
Thromb Haemost; 1999 May; 81(5):680-3. PubMed ID: 10365736
[TBL] [Abstract][Full Text] [Related]
19. Haplotypes of the endothelial protein C receptor gene and Behçet's disease.
Navarro S; Bonet E; Medina P; Martos L; Ricart JM; Vayá A; Todolí J; Fontcuberta J; Estellés A; España F
Thromb Res; 2012 Apr; 129(4):459-64. PubMed ID: 21851971
[TBL] [Abstract][Full Text] [Related]
20. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk.
Flinterman LE; van Hylckama Vlieg A; Rosendaal FR; Doggen CJ
Br J Haematol; 2010 Apr; 149(1):118-23. PubMed ID: 20096009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]